PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

David J Brooks Selected Research

Parkinson Disease (Parkinson's Disease)

06/2008	Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
05/2008	Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.
03/2008	Extrastriatal monoamine neuron function in Parkinson's disease: An (18)F-dopa PET study.
02/2008	Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.
01/2007	Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy.
10/2006	Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model.
03/2006	GDNF in treatment of Parkinson's disease: response to editorial.
03/2006	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
02/2006	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease.
12/2005	Factors affecting the clinical outcome after neural transplantation in Parkinson's disease.
03/2004	Cardiovascular effects of methamphetamine in Parkinson's disease patients.
07/2003	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
06/2003	PET studies on the function of dopamine in health and Parkinson's disease.
05/2003	Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
05/2003	Endogenous dopamine release after pharmacological challenges in Parkinson's disease.
02/2003	Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study.
07/2002	Dyskinesias following neural transplantation in Parkinson's disease.
06/2002	Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study.
03/2002	18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.

Articles by Research Topic

Disease

19	Parkinson Disease (Parkinson's Disease) 06/2008 - 03/2002
2	Epilepsy (Aura) 04/2007 - 06/2003
2	Dyskinesias (Dyskinesia) 11/2006 - 07/2002
1	Temporal Lobe Epilepsy 01/2008
1	Motor Neuron Disease (Primary Lateral Sclerosis) 08/2007
1	Alzheimer Disease (Alzheimer's Disease) 07/2006
1	Atrophy 07/2006
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2006
1	Chorea (Rheumatic Chorea) 12/2005
1	Sclerosis 06/2005
1	Restless Legs Syndrome (Restless Legs) 04/2005
1	Huntington Disease (Huntington's Disease) 05/2003
1	Dementia (Dementias) 06/2002

Drug/Important Bio-Agent (IBA)

6	Dopamine (Intropin)FDA LinkGeneric 05/2008 - 02/2003
5	Levodopa (L Dopa)FDA LinkGeneric 06/2008 - 06/2002
4	Flumazenil (Romazicon)FDA LinkGeneric 01/2008 - 06/2003
3	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 03/2006 - 05/2003
2	entacapone (Comtan)FDA Link 06/2008 - 02/2008
2	ropinirole (Requip)FDA LinkGeneric 11/2006 - 07/2003
2	PK 11195 (PK11195)IBA 02/2006 - 01/2006
1	fluorodopa F 18IBA 03/2008
1	Carbidopa (Lodosyn)FDA LinkGeneric 02/2008
1	Opioid Receptors (Opioid Receptor)IBA 04/2007
1	Amyloid (Amyloid Fibrils)IBA 07/2006
1	N- methyl- 2- (4'- methylaminophenyl)- 6- hydroxybenzothiazoleIBA 07/2006
1	Thyroxine (Levothyroxine)FDA LinkGeneric 12/2005
1	DiprenorphineIBA 04/2005
1	Opioid Analgesics (Opioids)IBA 04/2005
1	Methamphetamine (Desoxyn)FDA Link 03/2004
1	Dopamine Receptors (Dopamine Receptor)IBA 05/2003
1	tolcapone (Tasmar)FDA Link 03/2002

Therapy/Procedure

2	Transplantation (Transplant Recipients) 12/2005 - 07/2002